Abstract
Alzheimer’s disease (AD) is a neurological condition that causes behavioural abnormalities and a progressive decline in intellectual abilities. In the brain, metal ions equilibria are essential for appropriate brain functioning, while dyshomeostasis of free metal ions is associated with Alzheimer’s disease. In the brain, dysregulated metal ions trigger various responses, such as promoting Aβ(1–42) aggregation, tau hyperphosphorylation, oxidative stress, and disruption of organelles, which leads to autophagic failure. Approved drugs for AD only have palliative effects. Thus, potential molecules with contrasting features, such as chelating agents and metal-based medicines, have been proposed to act on various molecular targets to treat AD. This chapter aims to highlight the various applications and current advancements of metal-based medications, including metal complexes and metal-chelating agents, as potential therapeutic agents for treating AD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Acevedo KM, Hung YH, Dalziel AH, Li Q-X, Laughton K, Wikhe K, Rembach A, Roberts B, Masters CL, Bush AI, Camakaris J (2011) Copper promotes the trafficking of the amyloid precursor protein. J Biol Chem 286:8252–8262. https://doi.org/10.1074/JBC.M110.128512
Acevedo KM, Opazo CM, Norrish D, Challis LM, Li QX, White AR, Bush AI, Camakaris J (2014) Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells. J Biol Chem 289:11007–11019. https://doi.org/10.1074/JBC.M113.538710
Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59:43–55. https://doi.org/10.1016/j.neuron.2008.06.018
Antala S, Dempski RE (2012) The human ZIP4 transporter has two distinct binding affinities and mediates transport of multiple transition metals. Biochemistry 51:963–973. https://doi.org/10.1021/BI201553P
Bagheri S, Squitti R, Haertlé T, Siotto M, Saboury AA (2018) Role of copper in the onset of Alzheimer’s disease compared to other metals. Front Aging Neurosci 9:446. https://doi.org/10.3389/FNAGI.2017.00446/FULL
Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, Williamson NA, White AR, Hinds MG, Norton RS, Beyreuther K, Masters CL, Parker MW, Cappai R (2003) Structure of the Alzheimer’s disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 278:17401–17407. https://doi.org/10.1074/JBC.M300629200
Barr CA, Burdette SC (2017) The zinc paradigm for metalloneurochemistry. Essays Biochem 61:225–235. https://doi.org/10.1042/EBC20160073
Beck MW, Oh SB, Kerr RA, Lee HJ, Kim SH, Kim S, Jang M, Ruotolo BT, Lee J-Y, Lim MH (2015) A rationally designed small molecule for identifying an in vivo link between metal-amyloid-β complexes and the pathogenesis of Alzheimer’s disease. Chem Sci 6:1879–1886. https://doi.org/10.1039/c4sc03239j
Borgna-Pignatti C, Cohen A (1997) Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 130:86–88. https://doi.org/10.1016/S0022-3476(97)70314-7
Brewen GJ (2008) The risks of free copper in the body and the development of useful anticopper drugs. Curr Opin Clin Nutr Metab Care 11:727–732. https://doi.org/10.1097/MCO.0B013E328314B678
Carpenter MC, Shami Shah A, Desilva S, Gleaton A, Su A, Goundie B, Croteau ML, Stevenson MJ, Wilcox DE, Austin RN (2016) Thermodynamics of Pb(II) and Zn(II) binding to MT-3, a neurologically important metallothionein. Metallomics 8:605–617. https://doi.org/10.1039/c5mt00209e
Castilho RF, Ward MW, Nicholls DG (2001) Oxidative stress, mitochondrial function, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 72:1394–1401. https://doi.org/10.1046/J.1471-4159.1999.721394.X
Catterall WA (2011) Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 3:1–23. https://doi.org/10.1101/CSHPERSPECT.A003947
Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F (2018) Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol 14:450–464. https://doi.org/10.1016/J.REDOX.2017.10.014
Chen W, Wang Y, Wang H, An D, Sun D, Li P, Zhang T, Lu W, Liu Y (2021) TPEN attenuates amyloid-β25–35-induced neuronal damage with changes in the electrophysiological properties of voltage-gated sodium and potassium channels. Mol Brain 14:124. https://doi.org/10.1186/S13041-021-00837-Z
Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim YS, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:665–676. https://doi.org/10.1016/S0896-6273(01)00317-8
Chin-Chan M, Segovia J, Quintanar L, Arcos-López T, Hersh LB, Martin Chow K, Rodgers DW, Quintanilla-Vega B (2015) Mercury reduces the enzymatic activity of neprilysin in differentiated SH-SY5Y cells. Toxicol Sci 145:128–137. https://doi.org/10.1093/toxsci/kfv037
Choo XY, Alukaidey L, White AR, Grubman A (2013) Neuroinflammation and copper in Alzheimer’s disease. Int J Alzheimers Dis 2013:1–12. https://doi.org/10.1155/2013/145345
Clardy SL, Wang X, Zhao W, Liu W, Chase GA, Beard JL, True Felt B, Connor JR (2006) Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain. J Neural Transm Suppl 71:173–196. https://doi.org/10.1007/978-3-211-33328-0_19
Crouch PJ, Harding SME, White AR, Camakaris J, Bush AI, Masters CL (2008) Mechanisms of Aβ mediated neurodegeneration in Alzheimer’s disease. Int J Biochem Cell Biol 40:181–198. https://doi.org/10.1016/J.BIOCEL.2007.07.013
Crouch PJ, Lin WH, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li QX, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR, Barnham KJ (2009a) Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 106:381–386. https://doi.org/10.1073/PNAS.0809057106/SUPPL_FILE/0809057106SI.PDF
Crouch PJ, Tew DJ, Du T, Nguyen DN, Caragounis A, Filiz G, Blake RE, Trounce IA, Soon CPW, Laughton K, Perez KA, Li Q-X, Cherny RA, Masters CL, Barnham KJ, White AR (2009b) Restored degradation of the Alzheimer’s amyloid-β peptide by targeting amyloid formation. J Neurochem 108:1198–1207. https://doi.org/10.1111/J.1471-4159.2009.05870.X
Cummings JL, Morstorf T, Zhong K (2014) Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 6:37. https://doi.org/10.1186/ALZRT269
Dalvi T, Dewangan B, Das R, Rani J, Shinde SD, Vhora N, Jain A, Sahu B (2020) Old drugs with new tricks: paradigm in drug development pipeline for Alzheimer’s disease. Cent Nerv Syst Agents Med Chem 20:157–176. https://doi.org/10.2174/1871524920666201021164805
Dalvi T, Dewangan B, Agarwal G, Shinde Suchita D, Jain A, Srivastava A, Sahu B (2021) Design, synthesis and in-vitro evaluation of fluorinated triazoles as multi-target directed ligands for Alzheimer disease. Bioorg Med Chem Lett 42:127999. https://doi.org/10.1016/J.BMCL.2021.127999
Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, Li X, Moir RD, Tanzi RE, Bush AI, Kowall NW, Rogers JT, Huang X (2004) Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer’s amyloidogenesis. Exp Gerontol 39:1641–1649. https://doi.org/10.1016/j.exger.2004.08.016
Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J (2009) A role for synaptic zinc in activity-dependent Aβ oligomer formation and accumulation at excitatory synapses. J Neurosci 29:4004–4015. https://doi.org/10.1523/JNEUROSCI.5980-08.2009
Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li QX, Masters CL, Barnham KJ, White AR (2008a) Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 283:4568–4577. https://doi.org/10.1074/JBC.M705957200
Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li QX, Masters CL, Barnham KJ, White AR (2008b) Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-β peptide. J Biol Chem 283:4568–4577. https://doi.org/10.1074/jbc.M705957200
Dröge W, Schipper HM (2007) Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 6:361–370. https://doi.org/10.1111/J.1474-9726.2007.00294.X
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer’s disease: additional phase II analyses. J Alzheimers Dis 20:509–516. https://doi.org/10.3233/JAD-2010-1390
Frazzini V, Rockabrand E, Mocchegiani E, Sensi SL (2006) Oxidative stress and brain aging: is zinc the link? Biogerontology 7:307–314. https://doi.org/10.1007/S10522-006-9045-7
Fukada T, Yamasaki S, Nishida K, Murakami M, Hirano T (2011) Zinc homeostasis and signaling in health and diseases. J Biol Inorg Chem 16:1123–1134. https://doi.org/10.1007/S00775-011-0797-4/FIGURES/7
Grill J, Cummings J (2010) Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev Neurother 10(5):711–728. https://doi.org/10.1586/ERN.10.29
Gröber U, Schmidt J, Kisters K (2015) Magnesium in prevention and therapy. Nutrients 7:8199–8226. https://doi.org/10.3390/NU7095388
Grundke-Iqbal I, Iqbal K, Tung YC, Wisniewski HM (1984) Alzheimer paired helical filaments: immunochemical identification of polypeptides. Acta Neuropathol 62:259–267. https://doi.org/10.1007/BF00687607
Gu M, Bode DC, Viles JH (2018) Copper redox cycling inhibits Aβ fibre formation and promotes fibre fragmentation, while generating a dityrosine Aβ dimer. Sci Rep 8:16190. https://doi.org/10.1038/s41598-018-33935-5
Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY (2013) Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging 34:562–575. https://doi.org/10.1016/J.NEUROBIOLAGING.2012.05.009
Gupta SP (2018) Roles of metals in human health. MOJ Bioorg Org Chem 2(5):221–224. https://doi.org/10.15406/MOJBOC.2018.02.00085
Gybina AA, Tkac I, Prohaska JR (2009) Copper deficiency alters the neurochemical profile of developing rat brain. Nutr Neurosci 12:114–122. https://doi.org/10.1179/147683009X423265
Haas KL, Franz KJ (2009) Application of metal coordination chemistry to explore and manipulate cell biology. Chem Rev 109:4921–4960. https://doi.org/10.1021/cr900134a
Hordyjewska A, Popiołek Ł, Kocot J (2014) The many “faces” of copper in medicine and treatment. Biometals 27:611–621. https://doi.org/10.1007/S10534-014-9736-5
Horning KJ, Caito SW, Tipps KG, Bowman AB, Aschner M (2015) Manganese is essential for neuronal. Health 35:71–108. https://doi.org/10.1146/annurev-nutr-071714-034419
Huang L, Tepaamorndech S (2013) The SLC30 family of zinc transporters—a review of current understanding of their biological and pathophysiological roles. Mol Asp Med 34:548–560. https://doi.org/10.1016/J.MAM.2012.05.008
Huang W, Wei W, Shen Z (2014) Drug-like chelating agents: a potential lead for Alzheimer’s disease. RSC Adv 4:52088–52099. https://doi.org/10.1039/C4RA09193K
Hung YH, Bush AI, Cherny RA (2009) Copper in the brain and Alzheimer’s disease. J Biol Inorg Chem 15:1–15, 61–76. https://doi.org/10.1007/S00775-009-0600-Y
James SA, Churches QI, de Jonge MD, Birchall IE, Streltsov V, McColl G, Adlard PA, Hare DJ (2017) Iron, copper, and zinc concentration in Aβ plaques in the APP/PS1 mouse model of Alzheimer’s disease correlates with metal levels in the surrounding neuropil. ACS Chem Neurosci 8:629–637. https://doi.org/10.1021/ACSCHEMNEURO.6B00362/ASSET/IMAGES/LARGE/CN-2016-003625_0005.JPEG
Jiang H, Wang J, Rogers J, Xie J (2017) Brain iron metabolism dysfunction in Parkinson’s disease. Mol Neurobiol 54:3078–3101. https://doi.org/10.1007/S12035-016-9879-1
Jin L, Wu WH, Li QY, Zhao YF, Li YM (2011) Copper inducing Aβ42 rather than Aβ40 nanoscale oligomer formation is the key process for Aβ neurotoxicity. Nanoscale 3:4746–4751. https://doi.org/10.1039/C1NR11029B
Jolivet-Gougeon A, Bonnaure-Mallet M (2018) Treponema, iron and neurodegeneration. Curr Alzheimer Res 15:716–722. https://doi.org/10.2174/1567205013666161122093404
Kaden D, Bush AI, Danzeisen R, Bayer TA, Multhaup G (2011) Disturbed copper bioavailability in Alzheimer’s disease. Int J Alzheimers Dis 2011:345614. https://doi.org/10.4061/2011/345614
Kawamoto EM, Vivar C, Camandola S (2012) Physiology and pathology of calcium signaling in the brain. Front Pharmacol 3:61. https://doi.org/10.3389/FPHAR.2012.00061/BIBTEX
Kirkland AE, Sarlo GL, Holton KF (2018) The role of magnesium in neurological disorders. Nutrients 10:730. https://doi.org/10.3390/NU10060730
Klevay LM (2008) Alzheimer’s disease as copper deficiency. Med Hypotheses 70:802–807. https://doi.org/10.1016/j.mehy.2007.04.051
Krężel A, Hao Q, Maret W (2007) The zinc/thiolate redox biochemistry of metallothionein and the control of zinc ion fluctuations in cell signaling. Arch Biochem Biophys 463:188–200. https://doi.org/10.1016/J.ABB.2007.02.017
Kwan P, Ho A, Baum L (2022) Effects of deferasirox in Alzheimer’s disease and tauopathy animal models. Biomol Ther 12:365. https://doi.org/10.3390/BIOM12030365/S1
Lakatos A, Zsigó É, Hollender D, Nagy NV, Fülöp L, Simon D, Bozsó Z, Kiss T (2010) Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimer’s disease. Dalton Trans 39:1302–1315. https://doi.org/10.1039/B916366B
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779–786. https://doi.org/10.1016/S1474-4422(08)70167-4
Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 99:7705–7710. https://doi.org/10.1073/pnas.092034699
Lee JY, Friedman JE, Angel I, Kozak A, Koh JY (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol Aging 25:1315–1321. https://doi.org/10.1016/j.neurobiolaging.2004.01.005
Li Y, Jiao Q, Xu H, Du X, Shi L, Jia F, Jiang H (2017a) Biometal dyshomeostasis and toxic metal accumulations in the development of Alzheimer’s disease. Front Mol Neurosci 10:339. https://doi.org/10.3389/FNMOL.2017.00339/BIBTEX
Li DD, Zhang W, Wang ZY, Zhao P (2017b) Serum copper, zinc, and iron levels in patients with Alzheimer’s disease: a meta-analysis of case-control studies. Front Aging Neurosci 9:300. https://doi.org/10.3389/FNAGI.2017.00300/BIBTEX
Liu G, Men P, Harris PLR, Rolston RK, Perry G, Smith MA (2006) Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406:189–193. https://doi.org/10.1016/J.NEULET.2006.07.020
Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158:47–52. https://doi.org/10.1016/S0022-510X(98)00092-6
Lovell MA, Xiong S, Xie C, Davies P, Markesbery WR (2005) Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 6:659–671. https://doi.org/10.3233/JAD-2004-6610
Lutsenko S, Bhattacharjee A, Hubbard AL (2010) Copper handling machinery of the brain. Metallomics 2:596–608. https://doi.org/10.1039/C0MT00006J
Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, Salminen A, Auriola S, van Groen T, Tanila H, Koistinaho J (2007) Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting β-amyloid burden. J Neurosci 27:3712–3721. https://doi.org/10.1523/JNEUROSCI.0059-07.2007
Matlack KES, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S (2014) Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci U S A 111:4013–4018. https://doi.org/10.1073/pnas.1402228111
Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX (2005) Metals and amyloid-β in Alzheimer’s disease. Int J Exp Pathol 86:147–159. https://doi.org/10.1111/J.0959-9673.2005.00434.X
Moon Y, Han SH, Moon WJ (2016) Patterns of brain iron accumulation in vascular dementia and Alzheimer’s dementia using quantitative susceptibility mapping imaging. J Alzheimers Dis 51:737–745. https://doi.org/10.3233/JAD-151037
Moustakas M (2021) The role of metal ions in biology, biochemistry and medicine. Materials 14:1–4. https://doi.org/10.3390/MA14030549
Muhoberac BB, Vidal R (2013) Abnormal iron homeostasis and neurodegeneration. Front Aging Neurosci 5:32. https://doi.org/10.3389/FNAGI.2013.00032
Nayak P (2002) Aluminum: impacts and disease. Environ Res 89:101–115. https://doi.org/10.1006/ENRS.2002.4352
Nguyen M, Robert A, Sournia-Saquet A, Vendier L, Meunier B (2014) Characterization of new specific copper chelators as potential drugs for the treatment of Alzheimer’s disease. Chem Eur J 20:6771–6785. https://doi.org/10.1002/CHEM.201402143
Noël S, Perez F, Pedersen JT, Alies B, Ladeira S, Sayen S, Guillon E, Gras E, Hureau C (2012) A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation. J Inorg Biochem 117:322–325. https://doi.org/10.1016/J.JINORGBIO.2012.05.016
Paoletti P (2011) Molecular basis of NMDA receptor functional diversity. Eur J Neurosci 33:1351–1365. https://doi.org/10.1111/J.1460-9568.2011.07628.X
Parsons CG, Stöffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. Neuropharmacology 53:699–723. https://doi.org/10.1016/j.neuropharm.2007.07.013
Peña MMO, Lee J, Thiele DJ (1999) A delicate balance: homeostatic control of copper uptake and distribution. J Nutr 129:1251–1260. https://doi.org/10.1093/JN/129.7.1251
Petri S, Calingasan NY, Alsaied OA, Wille E, Kiaei M, Friedman JE, Baranova O, Chavez JC, Beal MF (2007) The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 102:991–1000. https://doi.org/10.1111/J.1471-4159.2007.04604.X
Rao SS, Portbury SD, Lago L, Bush AI, Adlard PA (2020) The iron chelator deferiprone improves the phenotype in a mouse model of tauopathy. J Alzheimers Dis 77:753–771. https://doi.org/10.3233/JAD-200551
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685–1691. https://doi.org/10.1001/ARCHNEUR.60.12.1685
Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR (2002) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 277:45518–45528. https://doi.org/10.1074/JBC.M207435200
Rogers JT, Venkataramani V, Washburn C, Liu Y, Tummala V, Jiang H, Smith A, Cahill CM (2016) A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity. J Neurochem 138:479–494. https://doi.org/10.1111/JNC.13671
Roland JR, Jacobsen H (2009) Alzheimer’s disease: from pathology to therapeutic approaches. Angew Chem Int Ed 48:3030–3059. https://doi.org/10.1002/ANIE.200802808
Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer P, Amit T, Mandel S, Youdim MBH (2015) Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer’s disease. Life Sci 136:108–119. https://doi.org/10.1016/J.LFS.2015.06.026
Santos MA, Chand K, Chaves S (2016) Recent progress in multifunctional metal chelators as potential drugs for Alzheimer’s disease. Coord Chem Rev 327–328:287–303. https://doi.org/10.1016/J.CCR.2016.04.013
Sayre LM, Perry G, Harris PLR, Liu Y, Schubert KA, Smith MA (2001) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease. J Neurochem 74:270–279. https://doi.org/10.1046/J.1471-4159.2000.0740270.X
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766. https://doi.org/10.1152/PHYSREV.2001.81.2.741
Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791. https://doi.org/10.1126/SCIENCE.1074069
Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426:900–904. https://doi.org/10.1038/nature02264
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/EMMM.201606210
Sensi SL, Granzotto A, Siotto M, Squitti R (2018) Copper and zinc dysregulation in Alzheimer’s disease. Trends Pharmacol Sci 39:1049–1063. https://doi.org/10.1016/J.TIPS.2018.10.001
Shin RW, Kruck TPA, Murayama H, Kitamoto T (2003) A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease. Brain Res 961:139–146. https://doi.org/10.1016/S0006-8993(02)03893-3
Singh SK, Sinha P, Mishra L, Srikrishna S (2013) Neuroprotective role of a novel copper chelator against Aβ 42 induced neurotoxicity. Int J Alzheimers Dis 2013:567128. https://doi.org/10.1155/2013/567128
Slutsky I, Sadeghpour S, Li B, Liu G (2004) Enhancement of synaptic plasticity through chronically reduced Ca2+ flux during uncorrelated activity. Neuron 44:835–849. https://doi.org/10.1016/j.neuron.2004.11.013
Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci U S A 100:11065–11069. https://doi.org/10.1073/pnas.1832769100
Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agró A (2002) D-penicillamine reduces serum oxidative stress in Alzheimer’s disease patients. Eur J Clin Investig 32:51–59. https://doi.org/10.1046/J.1365-2362.2002.00933.X
Su X-Y, Wu W-H, Huang Z-P, Hu J, Lei P, Yu C-H, Zhao Y-F, Li Y-M (2007) Hydrogen peroxide can be generated by tau in the presence of Cu(II). Biochem Biophys Res Commun 358:661–665. https://doi.org/10.1016/J.BBRC.2007.04.191
Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo D-G, Mattson MP, Tabaton M (2007) Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J Neurochem 2007:071115163316002. https://doi.org/10.1111/J.1471-4159.2007.05072.X
Tao Y, Wang Y, Rogers JT, Wang F (2014) Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimers Dis 42:679–690. https://doi.org/10.3233/JAD-140396
Tapiero H, Tew KD (2003) Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed Pharmacother 57:399–411. https://doi.org/10.1016/S0753-3322(03)00081-7
Tõugu V, Karafin A, Palumaa P (2008) Binding of zinc(II) and copper(II) to the full-length Alzheimer’s amyloid-β peptide. J Neurochem 104:1249–1259. https://doi.org/10.1111/j.1471-4159.2007.05061.x
Vassar R, Cole S (2007) The basic biology of BACE1: a key therapeutic target for Alzheimer’s disease. Curr Genomics 8:509–530. https://doi.org/10.2174/138920207783769512
Waggoner DJ, Bartnikas TB, Gitlin JD (1999) The role of copper in neurodegenerative disease. Neurobiol Dis 6:221–230. https://doi.org/10.1006/nbdi.1999.0250
Wang P, Wang ZY (2017) Metal ions influx is a double edged sword for the pathogenesis of Alzheimer’s disease. Ageing Res Rev 35:265–290. https://doi.org/10.1016/j.arr.2016.10.003
Wang ZX, Tan L, Wang HF, Ma J, Liu J, Tan MS, Sun JH, Zhu XC, Jiang T, Yu JT (2015) Serum iron, zinc, and copper levels in patients with Alzheimer’s disease: a replication study and meta-analyses. J Alzheimers Dis 47:565–581. https://doi.org/10.3233/JAD-143108
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13:1045–1060. https://doi.org/10.1016/S1474-4422(14)70117-6
White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI, Beyreuther K, Masters CL, Cappai R (1999a) The Alzheimer’s disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 19:9170–9179. https://doi.org/10.1523/JNEUROSCI.19-21-09170.1999
White AR, Reyes R, Mercer JFB, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R (1999b) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842:439–444. https://doi.org/10.1016/S0006-8993(99)01861-2
Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobágyi T, Johnson M, Attems J, Newhouse S, Ballard C, Thomas AJ, O’Brien JT, Aarsland D, Francis PT (2014) Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s disease: association with cognitive impairment. Neurobiol Aging 35:2836–2844. https://doi.org/10.1016/J.NEUROBIOLAGING.2014.06.015
Wischik CM, Harrington CR, Storey JMD (2014) Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol 88:529–539. https://doi.org/10.1016/J.BCP.2013.12.008
Wojsiat J, Zoltowska KM, Laskowska-Kaszub K, Wojda U (2018) Oxidant/antioxidant imbalance in Alzheimer’s disease: therapeutic and diagnostic prospects. Oxidative Med Cell Longev. https://doi.org/10.1155/2018/6435861
Xian-hui D, Wei-juan G, Tie-mei S, Hong-lin X, Jiang-tao B, Jing-yi Z, Xi-qing C (2015) Age-related changes of brain iron load changes in the frontal cortex in APPswe/PS1ΔE9 transgenic mouse model of Alzheimer’s disease. J Trace Elem Med Biol 30:118–123. https://doi.org/10.1016/J.JTEMB.2014.11.009
Xu W, Xu Q, Cheng H, Tan X (2017a) The efficacy and pharmacological mechanism of Zn7MT3 to protect against Alzheimer’s disease. Sci Rep 7:13763. https://doi.org/10.1038/s41598-017-12800-x
Xu W, Xu Q, Cheng H, Tan X (2017b) The efficacy and pharmacological mechanism of Zn7MT3 to protect against Alzheimer’s disease. Sci Rep 7:1–7. https://doi.org/10.1038/s41598-017-12800-x
Yehuda S, Youdim MBH, Hill JM, Levitsky DA (1989) Brain iron: a lesson from animal models. Am J Clin Nutr 50:618–629. https://doi.org/10.1093/AJCN/50.3.618
Yoshiike Y, Tanemura K, Murayama O, Akagi T, Murayama M, Sato S, Sun X, Tanaka N, Takashima A (2001) New insights on how metals disrupt amyloid β-aggregation and their effects on amyloid-β cytotoxicity. J Biol Chem 276:32293–32299. https://doi.org/10.1074/JBC.M010706200
Zhang L-H, Wang X, Stoltenberg M, Danscher G, Huang L, Wang Z-Y (2008) Abundant expression of zinc transporters in the amyloid plaques of Alzheimer’s disease brain. Brain Res Bull 77:55–60. https://doi.org/10.1016/J.BRAINRESBULL.2008.03.014
Zhang Z, Miah M, Culbreth M, Aschner M (2016) Autophagy in neurodegenerative diseases and metal neurotoxicity. Neurochem Res 41:409–422. https://doi.org/10.1007/s11064-016-1844-x
Zheng W, Xin N, Chi Z-H, Zhao B-L, Zhang J, Li J-Y, Wang Z-Y (2009) Divalent metal transporter 1 is involved in amyloid precursor protein processing and Aβ generation. FASEB J 23:4207–4217. https://doi.org/10.1096/FJ.09-135749
Zheng Z, White C, Lee J, Peterson TS, Bush AI, Sun GY, Weisman GA, Petris MJ (2010) Altered microglial copper homeostasis in a mouse model of Alzheimer’s disease. J Neurochem 114:1630–1638. https://doi.org/10.1111/J.1471-4159.2010.06888.X
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Dewangan, B., Kumar, K., Kumar, A., Bodhe, P.R., Beni, S., Sahu, B. (2023). Metal Chelators as a Potential Therapeutic Agent for Alzheimer’s Disease. In: Sharma, A., Modi, G.P. (eds) Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease. Springer, Singapore. https://doi.org/10.1007/978-981-99-6038-5_13
Download citation
DOI: https://doi.org/10.1007/978-981-99-6038-5_13
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-6037-8
Online ISBN: 978-981-99-6038-5
eBook Packages: MedicineMedicine (R0)